Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 5
1996 2
1997 3
1998 5
1999 2
2000 1
2001 1
2002 1
2003 1
2005 2
2006 1
2007 4
2008 8
2009 6
2010 4
2011 3
2012 5
2013 4
2014 4
2015 8
2016 9
2017 3
2018 9
2019 5
2020 11
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

100 results
Results by year
Filters applied: . Clear all
Page 1
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J. Kauko O, et al. Among authors: westermarck j. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. doi: 10.1126/scitranslmed.aaq1093. Sci Transl Med. 2018. PMID: 30021885
UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis.
Qiao X, Liu Y, Prada ML, Mohan AK, Gupta A, Jaiswal A, Sharma M, Merisaari J, Haikala HM, Talvinen K, Yetukuri L, Pylvänäinen JW, Klefström J, Kronqvist P, Meinander A, Aittokallio T, Hietakangas V, Eilers M, Westermarck J. Qiao X, et al. Among authors: westermarck j. Cancer Res. 2020 Apr 1;80(7):1414-1427. doi: 10.1158/0008-5472.CAN-19-1647. Epub 2020 Feb 6. Cancer Res. 2020. PMID: 32029551 Free article.
Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
Kauko O, Imanishi SY, Kulesskiy E, Yetukuri L, Laajala TD, Sharma M, Pavic K, Aakula A, Rupp C, Jumppanen M, Haapaniemi P, Ruan L, Yadav B, Suni V, Varila T, Corthals GL, Reimand J, Wennerberg K, Aittokallio T, Westermarck J. Kauko O, et al. Among authors: westermarck j. J Biol Chem. 2020 Mar 27;295(13):4194-4211. doi: 10.1074/jbc.RA119.011265. Epub 2020 Feb 18. J Biol Chem. 2020. PMID: 32071079 Free PMC article.
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, Brautigan DL, Haider S, Jackson M, Narla G. O'Connor CM, et al. Among authors: westermarck j. Oncogene. 2020 Jan;39(3):703-717. doi: 10.1038/s41388-019-1012-2. Epub 2019 Sep 20. Oncogene. 2020. PMID: 31541192 Free PMC article.
CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling.
Khan MM, Ullah U, Khan MH, Kong L, Moulder R, Välikangas T, Bhosale SD, Komsi E, Rasool O, Chen Z, Elo LL, Westermarck J, Lahesmaa R. Khan MM, et al. Among authors: westermarck j. iScience. 2020 Mar 27;23(3):100947. doi: 10.1016/j.isci.2020.100947. Epub 2020 Feb 27. iScience. 2020. PMID: 32171124 Free PMC article.
100 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page